Mometasone
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Mometasone
- Pharmacist Assessment Report
- Mometasone: From Corticosteroid-Responsive Inflammatory Conditions to Primary Cutaneous T-Cell Lymphoma
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Mometasone: From Corticosteroid-Responsive Inflammatory Conditions to Primary Cutaneous T-Cell Lymphoma
One-Sentence Summary
Mometasone is a potent corticosteroid marketed in India as nasal sprays and topical creams, ointment and gel, used for allergic and inflammatory conditions. The TxGNN model predicts it may be effective for primary cutaneous T-cell lymphoma, but there are currently no registered clinical trials and only 2 case reports that mention it, so the support is mainly a model prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Indian licence data. Reference pharmacology describes intranasal use for asthma, allergic rhinitis and nasal polyposis, and topical use for allergic skin disorders |
| Predicted New Indication | Primary cutaneous T-cell lymphoma |
| TxGNN Prediction Score | 0.9936 |
| Evidence Level | L5 (model prediction only; the two case reports do not provide mometasone-specific evidence) |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Based on known pharmacology, mometasone is a potent corticosteroid that acts on the glucocorticoid receptor (NR3C1). Activating this receptor suppresses T-cell activation and inflammatory cytokine production, and gives anti-inflammatory, immunosuppressive and antiproliferative effects.
Primary cutaneous T-cell lymphomas, the most common being mycosis fungoides, are driven by malignant T cells in the skin. Topical corticosteroids are an accepted skin-directed treatment for early-stage (patch/plaque) disease. This gives the prediction a plausible biological link, particularly for the topical forms of mometasone, which are already marketed in India.
The high score should be read with caution. It likely reflects class-level corticosteroid associations rather than mometasone-specific data, and none of the data compiled here shows mometasone benefiting patients with this lymphoma.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40821495 | 2025 | Case report | Proceedings (Baylor University Medical Center) | Refractory cutaneous pseudolymphoma (a benign look-alike of lymphoma) that failed mometasone and tacrolimus, then was treated with tapinarof. It does not support mometasone efficacy |
| 25442255 | 2015 | Case report | Journal of Cutaneous Pathology | Childhood mycosis fungoides with a CD8+ CD56+ cytotoxic immunophenotype in an 11-year-old boy. The abstract excerpt available does not describe mometasone results |
India Market Information
Twenty valid single-ingredient licences are registered; the five main ones are listed below. Approved indication text is not provided in the licence records.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 108133 | Isomet-M Nasal Spray | 100 MDI nasal spray | Not stated |
| 1872 | Aquamet Nasal Spray | 12 ml bottle, nasal spray | Not stated |
| 72468 | Elocon Cream | 10 g tube, cream | Not stated |
| 137979 | Midsone 0.1% Cream | 15 g tube, cream | Not stated |
| 48801 | Clearoid 0.1% Gel | 10 g tube, gel | Not stated |
The 20 licences cover nasal sprays, creams, an ointment and a gel. The topical forms are relevant to a skin-directed use in cutaneous lymphoma.
Safety Considerations
- Drug Interactions: The interaction query completed with one entry, which is a pharmacological target relationship (glucocorticoid receptor, NR3C1) rather than an interaction with another drug.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high and topical corticosteroids are an accepted option in early-stage mycosis fungoides, but no mometasone-specific clinical trials or supporting studies were found. The evidence is a model prediction only, and the package insert safety information is missing.
To proceed, the following is needed:
- Mometasone-specific clinical or observational data in primary cutaneous T-cell lymphoma, such as early-stage mycosis fungoides
- Detailed mechanism-of-action data from DrugBank
- Package insert warnings and contraindications for the marketed Indian products
- Approved indication text for the Indian licences, to confirm the original indication
- Confirmation that the topical products are suitable for this use (route and formulation compatibility)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.